Pesquisar um medicamento órfão
Outras opções de pesquisa
Designação órfã retirada - Europa
- Nome de comercialização: VENCLYXTO
- Código ATC: L01XX52
- Número EU: EU/1/16/1138
- Data da MA: 07/12/2016
- Detentor da MA: ABBVIE DEUTSCHLAND GMBH & CO. KG
- Relatório Público Europeu de Avaliação (EPAR)
In combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.
Venclyxto monotherapy is indicated for the treatment of CLL:
- in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor, or
- in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.